# Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome

> **NCT06261502** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Université de Sherbrooke** · enrollment: 40 (estimated)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** CBD Oral Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06261502
- **Lead sponsor:** Université de Sherbrooke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06261502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06261502, "Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06261502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*